The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline
for Diabetes” which has been revised every three years since its first appearance in 2004 to …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Recurrent stroke affects 9% to 15% of people within 1 year. This European Stroke
Organisation (ESO) guideline provides evidence-based recommendations on …

Aims/hypothesis Metformin is the most-prescribed oral medication to lower blood glucose
worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in …

Since its inception in 2004, the “Clinical Practice Guidelines for the Treatment of Diabetes”
has attempted to promote evidence-based, rational, efficient and standardized clinical …

Metformin has been the mainstay of therapy for diabetes mellitus for many years; however,
the mechanistic aspects of metformin action remained ill-defined. Recent advances revealed …

Importance Metformin is widely viewed as the best initial pharmacological option to lower
glucose concentrations in patients with type 2 diabetes mellitus. However, the drug is …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted as the document was compiled through …

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for
type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose …

Considerable efforts have been made since the 1950s to better understand the cellular and
molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now …